Psychological Burden in ICU Survivors of Severe COVID-19 Pneumonia, Their Relatives and Their Healthcare Providers
NCT ID: NCT04341519
Last Updated: 2020-10-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1464 participants
OBSERVATIONAL
2020-04-06
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main objective of this study is to demonstrate that the COVID-19 pandemic, as compared to seasonal flu and community acquired pneumonia, significantly increases post-traumatic stress disorder (PTSD) in family members of critically ill patients.
PTSD-related symptoms will be assessed in family members using the IES-R (impact of event scale revised) during a telephone interview 90 days after ICU discharge. The IES-R is a 22-item self-report measure that assesses subjective distress caused by traumatic events. It will be compared across the three groups (COVID-19, FLU and CAP).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of SARS-CoV-2 Effect on Post-traumatic Stress of Patients Hospitalized in Intensive Care Unit
NCT04872049
Impact of Covid-19 Restrictive Measure on Anxiety, Depression and PTSD for Relatives of ICU Patients
NCT04430049
Stress Related Disorders in Family Members of COVID-19 Patients Admitted to the ICU
NCT04476914
Evaluation of Psychological Impact of Group Therapy for Patients Who Have Been Hospitalized in Intensive Care During COVID-19 Pandemic: Exploratory Study
NCT04747405
Psychological Symptoms and Families of COVID-19 Patients
NCT04501445
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Family members
* Age\>18y
* Non-opposition to participate to the telephone interviews
* One family member per patient: the family member the most implicated in the patient's care
3 groups of Family members will be enrolled in the study corresponding to patients with COVID-19, patients with seasonal flu and patients with community acquired pneumonia (See below). 1 family member per patient will be recruited.
PTSD
family members: post-traumatic stress disorder (PTSD) related symptoms assessed by Impact of Event Scale Revised (IES-R) at 90 days
Patients:
post-traumatic stress disorder (PTSD) related symptoms assessed by Impact of Event Scale Revised (IES-R) at 90 days
Patients
Patients:
* Age\>18y
* Admission to the participating ICUs for any cause of acute respiratory failure during the COVID-19 pandemic
* Having received invasive or noninvasive mechanical ventilation
* Non-opposition to participate to the telephone interviews.
3 groups of patients will be enrolled in the study: patients with COVID-19, patients with seasonal flu and patients with community acquired pneumonia.
* COVID group : Patients admitted to the ICU for acute respiratory failure and having a positive 2019-nCOV RT PCR in a respiratory / nasal swab sample (GROUP COVID-19)
* Group FLU : patients admitted to the ICU for acute respiratory failure and having a confirmed influenza pneumonia
* Group CAP (Community-acquired pneumonia) : patients admitted to the ICU for acute respiratory failure and having a clinically or microbiologically documental community acquired pneumonia with negative COVID-19 and Influenza PCRs.
PTSD
family members: post-traumatic stress disorder (PTSD) related symptoms assessed by Impact of Event Scale Revised (IES-R) at 90 days
Patients:
post-traumatic stress disorder (PTSD) related symptoms assessed by Impact of Event Scale Revised (IES-R) at 90 days
healthcare providers
Two months after the official end of the COVID-19 peak in France, the local investigator will receive a set of 100 questionnaires. He/she will be responsible for proposing survey participation to volunteer healthcare providers. Those who are interested will be given the information letter and the questionnaires in an envelope. Once completed anonymously, they will seal the envelope and give it to the local investigator who will then send us all completed questionnaires by registered post.
Burnout
Symptoms of burnout as assessed by the Maslash Burnout Inventory
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PTSD
family members: post-traumatic stress disorder (PTSD) related symptoms assessed by Impact of Event Scale Revised (IES-R) at 90 days
Patients:
post-traumatic stress disorder (PTSD) related symptoms assessed by Impact of Event Scale Revised (IES-R) at 90 days
Burnout
Symptoms of burnout as assessed by the Maslash Burnout Inventory
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age\>18y
* Admission to the participating ICUs for any cause of acute respiratory failure during the COVID-19 pandemic
* Having received invasive or noninvasive mechanical ventilation
* Non-opposition to participate to the telephone interviews.
Family members:
* Age\>18y
* Non-opposition to participate to the telephone interviews
* One family member per patient: the family member the most implicated in the patient's care
Healthcare providers:
* All nurses and physicians (including those in training) in the participating ICUs during the COVID-19 pandemic
Exclusion Criteria
* Language barrier to be able to respond to the telephone interview
* Cognitive disorders disabling patients to respond to the telephone interview
* Person under legal protection (1121-8 of CSP, Public Health Code) Failure to obtain the non-opposition
Family members:
* Language barrier to be able to respond to the telephone interview
* Person under legal protection (1121-8 of CSP, Public Health Code)
* Failure to obtain the non-opposition
Healthcare providers:
Failure to obtain the non-opposition
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Elie AZOULAY, MD PhD
Role: PRINCIPAL_INVESTIGATOR
APHP
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cochin
Paris, , France
Pitié Salpetrière
Paris, , France
Saint-Louis Hospital
Paris, Île-de-France Region, France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Azoulay E, Resche-Rigon M, Megarbane B, Reuter D, Labbe V, Cariou A, Geri G, Van der Meersch G, Kouatchet A, Guisset O, Bruneel F, Reignier J, Souppart V, Barbier F, Argaud L, Quenot JP, Papazian L, Guidet B, Thiery G, Klouche K, Lesieur O, Demoule A, Guitton C, Capellier G, Mourvillier B, Biard L, Pochard F, Kentish-Barnes N. Association of COVID-19 Acute Respiratory Distress Syndrome With Symptoms of Posttraumatic Stress Disorder in Family Members After ICU Discharge. JAMA. 2022 Mar 15;327(11):1042-1050. doi: 10.1001/jama.2022.2017.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APHP200389
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.